Analyst consensus rating
Lifecore Biomedical Analyst Rating: Buy
LFCR is rated Buy by 3 analysts with a $6.75 target. As of 2026-08-24.
Direct answer
Lifecore Biomedical's consensus rating is Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.75.
Forecast evidence checked August 24, 2026.
Get free Lifecore Biomedical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.54
- Average price target
- $6.75
- High price target
- $9.00
- Low price target
- $5.00
- Low target gap
- +10.1%
- Target upside
- +48.7%
- High target gap
- +98.2%
- Target range width
- 88.1%
- Consensus rating
- Buy
- Analysts
- 3
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lifecore Biomedical?
Lifecore Biomedical has a verified Buy consensus. The same dataset has an average price target of $6.75.
How far are Lifecore Biomedical's low and high targets from the recorded price?
The low target implies +10.1%, while the high target implies +98.2%.
How many analysts are included in Lifecore Biomedical's consensus?
The verified consensus includes 3 analysts.
How is Lifecore Biomedical's target upside or downside calculated?
The average target of $6.75 is divided by the recorded price of $4.54, then one is subtracted to produce +48.7%. This does not guarantee a future return.
When was Lifecore Biomedical's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.